Bile acids (BAs) are a group of chemically-related steroids recognized as regulatory molecules whose profiles can change in different physio-pathological situations. We have developed a sensitive, fast and reproducible UPLC-MRM-MS method to determine the tissue and sera BA profiles in different species (human, rat and mouse) by quantifying 31 major and minor BA species in a single 21-min run. The method has been validated according to FDA guidelines, and it generally provides good results in terms of intra-and inter-day variation (less than 8.6% and 16.0%, respectively), accuracy (relative error measurement between -11.9% and 8.6%) and linearity (R 2 > 0.996 and dynamic ranges between 2 and 4 orders of magnitude), with limits of quantification between 2.5 and 20
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INTRODUCTION
Bile acids (BAs) are major components of bile formed from cholesterol through various enzymatic reactions in hepatocytes. Before being excreted into bile canaliculi, primary
BAs synthesized in the liver (i.e., CA and CDCA in humans, plus αMCA and βMCA in rodents) (1, 2) are mainly conjugated with taurine or glycine amino acids through the terminal side-chain carboxylic group present in the BA structure. Once in the intestine, primary BAs are de-conjugated and converted into secondary BAs by microbiota. Then, most BAs are reabsorbed back to the liver, conjugated by hepatocytes and re-excreted into bile to complete enterohepatic circulation (3).
In the past, BAs were considered to be mere detergents required for the solubilization and absorption of dietary fats; nowadays however, BAs are recognized as regulatory molecules capable of activating specific receptors. BAs are physiological ligands for the farnesoid X receptor (FXR), an intracellular BA sensor which controls the expression of the genes involved in BA synthesis, metabolism and transport in order to minimize the deleterious effects of their accumulation (4, 5) . BAs are also able to bind other nuclear receptors (e.g.,. PXR or VDR) and G-protein coupled receptor TGR5, and can also activate several cell signaling pathways (i.e., JNK, ERK or AKT) (5) (6) (7) (8) . By activating these receptors and signaling cascades, BAs regulate not only their own homeostasis, but also fatty acid, lipoprotein, glucose and energy metabolism (5, 7, 9) . The primary signaling function of BAs seems to be the regulation of metabolic flux in the liver and the gastrointestinal tract during the feed/fast cycle; however, they are also involved in the control of cell proliferation and inflammatory processes (5, 9) .
The BA pool constitutes a large mixture of chemically-related steroids, including isomeric forms, with diverse physicochemical properties and biological functions.
Physiological concentrations of circulating BAs in healthy subjects are low; a number of conditions, including hepatobiliary and intestinal diseases or drug-induced liver injury, can alter BA homeostasis, leading to increased BA levels (10) (11) (12) . Accumulation of BAs is considered a hallmark of chronic cholestatic liver disease; more specifically, it has been shown that its deleterious toxic effects depend on the profile of accumulated BAs (13) . In particular, hydrophobic species (i.e., CDCA, LCA or DCA) and their conjugates have been reported to be highly cytotoxic, and their accumulation can damage hepatic cells from inducing mitochondrial dysfunction, oxidative stress or apoptosis (14) . (GCA-d4) were purchased from Steraloid inc (Newport, USA).
UPLC-MS analysis
UPLC separation was performed in an Acquity UPLC system (Waters, U.K.) equipped with an Acquity UPLC BEH C18 (1.7um, 2.1x100mm, Waters) column. The temperatures of the column and the autosampler were set at 65ºC and 4ºC, respectively.
The sample injection volume was 4 µl. Eluents consisted in 0.1% formic acid in water (eluent A) and 0.1% formic acid in acetonitrile (eluent B). The flow rate was set at 0.5mL/min. A 21-min elution gradient was performed as follows: during the first 0.5 min, eluent composition was set at 95% A and 5% B, which was linearly changed to 75% A and 25% B in 5 min, then the proportion of B was increased to 40% in the next 10.5 min, followed by a further increase to 95% B reached at min 17.5 and kept for 1.5 min. Finally, the initial conditions were recovered and maintained for 2 min for column conditioning.
The MS analysis was performed using a Waters Xevo TQ-S mass spectrometer (Waters, UK) equipped with an ESI source in the negative-ion mode working in the multiple reaction monitoring (MRM) mode. A capillary voltage of 2 kV, a source temperature of 120°C and a desolvation temperature of 380°C were used. Desolvation and the cone gas flow were set as 800 L/h and 150 L/h, respectively, while the collision gas was 0.25 mL/min. Transitions, cone voltages and collision energies were automatically tuned for each BA using the Quanoptimizer software (Waters, UK). The data station operating software used was MassLynx 4.1 (Waters, U.K.). 
Sample collection
Rat and mouse studies
Six-week-old male OFA rats (200-240 g) and 6-week-old male C57BL/6 mice (20-22 g)
were purchased from Charles River (Barcelona, Spain) and acclimatized to laboratory conditions for at least 7 days. Animals were housed (12-hour light: dark cycle, 21-25ºC, 30-70% humidity, woodchip bedding) and fed ad libitum with a standard chow diet (SAFE (Scientific Animal Food and Engineering), Augy, France).
Rats were anesthetized with sodium thiobarbital (0.1 g/kg) and mice were anesthetized with a mixture of ketamine/diazepam/atropine (50/5/1 mg/kg). In rats, blood was collected by cardiac puncture, whereas it was obtained from the abdominal aorta in mice. After coagulation and centrifugation (10 min, 1000 g, 4ºC), serum samples were aliquoted and stored at -80ºC until the analysis. Livers were removed, rinsed in PBS, divided into small portions, flash-frozen in liquid N 2 and stored at -80ºC until the analysis. Serum and liver samples were obtained from the same animals. All the experimental protocols were approved by the Institutional Animal Ethics Committee.
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Human studies
Blood samples were collected from healthy human volunteers by standard venipunction.
After sample centrifugation, sera were aliquoted and stored at -80ºC until the analysis.
Human liver samples were obtained from cadaveric liver grafts. These samples were obtained at the end of the bench surgery during the cold ischemia time, and were immediately frozen in liquid N 2 and stored at -80ºC until the analysis. Informed consent was obtained in all cases, and the experimental procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the Institutional Ethics Committee.
Sample preparation
Serum samples
First, 50 µL of serum samples were allowed to thaw on ice and were subsequently spiked with 25 µL of a 1/100 dilution of the deuterated IS stock solution. Afterward, 225 µL of cold methanol were added for protein precipitation, and samples were then 
Method validation
The bioanalytical method used in this study was developed in terms of linearity, accuracy and precision following the compliance criteria described by the FDA Guidance for industry: bioanalytical method validation (27).
The lower limit of quantification (LLOQ) was defined as the lowest concentration at which the analyte could be quantified with a coefficient of variation below 20% and below ± 20% deviation from the nominal value. Limit of detection (LOD) was determined as the lowest concentration at which the analyte response was at least three times the blank response. Calibration curves were generated by plotting the peak area ratio of the respective compound to the corresponding internal standard versus the nominal concentration (Table 1 ). The line of best fit was determined by linear-weighted (1/x) least-squares regression. The linearity acceptance criterion for the correlation coefficient was 0.99, or better. Each back calculated standard concentration should be within ±15% deviation from the nominal value, except for the LLOQ, for which the maximum acceptable deviation was ±20%.
Intra-day and inter-day precision and accuracy were determined by analyzing individual BAs in three different QCs corresponding to low (40 nM), medium (312 nM) and high (2500 nM) representative concentrations. The IS concentration was maintained constant in all the QCs (i.e., 1 µM for LCA-D4 and 0.5 µM for CA-D4, DCA-D4, GCA-D4 and GCDCA-D4). Each QC was analyzed five times in three different experimental samples batches. The acceptance criteria for precision within and between batches, expressed as a coefficient of variation (CV), were ±20% for the LLOQ and ±15% or better for the other concentrations. Accuracy is expressed as the relative measurement error (RME) and was calculated using the following formula: RME (%) = 100 x (calculated concentration -nominal concentration)/nominal concentration. The acceptance criteria were ±20% for within and between batches for the LLOQ and ±15% or better for the other concentrations.
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To account for possible matrix effects in BA recoveries and method accuracy, pooled samples were obtained for each specimen type (i.e., serum and tissue) and animal species (i.e., rat, mouse, and human). Then endogenous BAs were stripped off by activated charchoal incubation, as previously described (21 were respectively selected as the precursor ions for mono-, di-and tri-hydroxylated and TDHCA bile acids, and an m/z value of 80 (the SO3 -anion from the taurine moiety) was selected as the product ion. The deuterated BAs used in our study as IS showed similar fragmentation profiles to their corresponding non deuterated counterparts (Table 1) .
Serum and tissue liver sample preparation
Most methods used to target BAs in serum involve the removal of proteins by precipitation using organic solvents, followed by a solid phase-extraction (SPE) (12, 22, 24, (28) (29) (30) (31) (32) (33) . On the other hand, preparation of liver tissue involves a homogenization step, usually followed by an SPE step (17, 34) . SPE is used to concentrate the compounds of interest and to eliminate possible analytical interferences. After testing the behavior of different SPE matrices, surprisingly, low recovery efficiencies were obtained for a number of BAs (data not shown). Thus to minimize sample handling and any possible bias, serum samples were processed by simple protein precipitation with methanol, followed by solvent evaporation and a final reconstitution of the pellet immediately prior to its analysis. As regards liver sample preparation, a previous homogenization step before protein precipitation was carried out. In both procedures, five deuterated ISs (CA-D4, DCA-D4, LCA-D4, GCA-D4 and GCDCA-D4) were added at the beginning of the sample treatment procedure to account for any possible bias during the sample processing procedure.
The reproducibility of the serum processing method was assayed by analyzing six different preparations of one commercially available pooled human serum (SigmaAldrich, Spain) four times. The CV (%) in the quantification of individual BAs ranged from 1.1 to 11.6 in the four injection replicates and from 0.8 to 8.1 for the six serum preparations (see Supplemental Material Table S1 ). These results demonstrate the by guest, on October 14, 2017
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reproducibility and reliability of the serum sample preparation procedure employed in our study.
One important question about the tissue analysis, particularly in the case of the liver where different structural and functional domains are present, is assessing whether a small singular portion of tissue (i.e., a liver biopsy) is representative of the whole organ.
To assess the representativeness of a liver biopsy in quantitative BA profiling, seven liver biopsies were randomly taken from different lobes of a rat liver and each BA was further analyzed. In brief, the accuracy and precision quantification results show appropriate accuracies for all the BAs, with only a slight deviation in the determination of LCA and GLCA, two of the minor species present in the BA pool (Supplementary Material Table S2 ).
Method Validation
The UPLC-MS method was validated in terms of accuracy, precision and linearity.
Furthermore, the possible matrix effects and bias during the analysis were also studied.
Overall accuracy and precision were appropriate for all the determinations. Intra-day and inter-day accuracies, measured as RME, ranged from -11.9% to 8.6%. Precision, measured as CV (%), was below 8.6 and 16.0 for intra-and inter-day, respectively (Table 2 ). In terms of linearity, the regression coefficients for all the calibration curves of the BAs were higher than 0.996. Calibration curve concentrations were increased to 10 µM, although linearity was maintained at higher concentrations for some BAs.
Wide dynamic linear ranges of quantification, from 2 to 4 orders of magnitude depending on the BA, and high sensitivity (LLOQ ranging from 2.5 to 20 nM and LOD from 0.6 to 10 nM), were achieved by the combined used of UPLC tandem modern MS instruments operating in the MRM mode.
Any possible matrix effects in BA recoveries during sample preparation and analysis were also studied. To this end, endogenous BAs were stripped off from the different biological matrices by incubation with activated charcoal. Afterward, known amounts of BAs were added to each stripped matrix and to blanks. The accuracy of BA quantification was calculated for each matrix at three different concentrations (i.e., low, medium and high). Accuracy values ranged from -19.1% to 29.0% (expressed as RME), with only 7 of the 651 determinations beyond the ± 20% range (see Supplemental
Material Table S3 ).
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Bile acids profiling in human, rat and mouse serum and in liver specimens
The UPLC-MRM-MS method was satisfactorily applied to quantify the major and minor BAs present in human, rat and mouse serum and in liver samples. The quantitative results for the serum and liver BAs profiling are respectively summarized in Table 3 and Table 4 . In terms of total amount of BAs, the human species was seen to have the lowest BAs content in both liver and serum, rat had the highest concentration in serum, and mouse showed the highest BA content in the liver. As expected, the proportion of non conjugated BAs was higher in serum than in the liver samples in all three species (Supplementary Material Figure S7 ). Glycine-conjugated BAs were the most abundant in the human liver, whereas tauro-BAs were the predominant conjugated forms in rodents, with glycine-conjugates being practically absent in mouse.
In order to gain a more in-depth and easier insight into intra-and inter-species BAs patterns, a unsupervised cluster analysis of the BA quantitative results was performed (Fig. 2) . Despite the fact that a different profile of individual BAs was found between rat and mouse serum, non conjugated BAs represented more than 80% in both species.
CA was the most abundant form in rat serum (50% of the total), followed by αMCA (12%), βMCA (10%) and CDCA (7%), whereas CA (24%), ωMCA (24%), βMCA The method has been validated in terms of repeatability, precision, accuracy, and linearity by following the validation criteria established by the FDA (27). Overall, intra-and interday variations are under 16%, while accuracy, expressed as RME, is below 11% ( Table   2 ). The validation results not only demonstrate the robustness of the method, but also guarantee sufficient sensitivity and specificity for the reliable quantification of the 31 are based on the quantitative analysis of a few predefined targets, with very little attention being paid to the less abundant forms (19) . This fact is a major drawback, particularly for those studies that centre on comparing the profiles of BAs (e.g., healthy and disease populations) where not only changes in the major BAs, but also in the minor ones, have been associated with several hepatobiliary diseases or liver damage conditions. For instance, significant alterations in the levels of some minor BAs (<1% of the total BA pool) have been reported in serum from patients with cholestasic liver diseases (13, 28) , in plasma and urine from a genetic model of cholestasis in rats (31) , in serum of rats treated with hepatotoxins (12) and in rat bile and liver samples during chemically induced hepatocarcinogenesis (37). Moreover, an in vitro study has suggested that LCA, a minor BA form, plays an important role in controlling the expression of several proteins involved in BA synthesis, metabolism and transport (6) . LCA is a promiscuous ligand capable of interacting with FXR, VDR and PXR. It is considered a toxic BA with carcinogenic potential in the intestine, and has shown cholestatic capacity in the liver of animals and men. Overall, these findings evidence the interest of a method, like that presented herein, which is able to identify changes in a broad spectrum of BA species, including those present at relatively low concentrations.
BA composition in biological fluids (mainly serum, but also bile or urine) has been extensively investigated. The patterns of BAs that we obtained in serum samples from each species are in good agreement with those reported by other authors. However, our method provides a more specific and comprehensive profiling of BAs in rodents than previous reports in which α-, β-, and ω-MCA, and their taurine conjugates, were not properly quantified (12, 23, 31) . When using our method, not only primary and secondary BAs, the most commonly analyzed forms, but also free and conjugated 6αhydroxylated species, can be accurately quantified. This allowed us to identify detectable levels of GHCA and THCA in human serum, thus extending previous studies which only showed the presence of the non conjugated HCA homolog (10, 13). Furthermore, it was also possible to detect, for the first time, TαMCA in healthy human serum. These BAs, considered a priori unusual or non human-specific BAs, have been detected by us in patients with severe liver diseases (unpublished results from our laboratory) and by others in different pathophysiological studies (26, 38, 39) . (20) . We have recently reported altered levels of some BAs, including taurine and glycine conjugates, in the liver of patients suffering non alcoholic fatty liver disease (17) . However, to the best of our knowledge, comprehensive profiling of BAs in human liver tissue has not been performed to date. Our results show that GCDCA is the most abundant BA in the human liver (31% of the total pool), which represents a notable difference to rodents. Conjugated forms (glycine and taurine) of CDCA, a primary BA in humans, represent about 50% of the total BA pool in the human liver, whereas the total CA and MCA forms (α, β, or ω) are predominant in rodents (>80% of the total). These interspecies differences in the hepatic BA pool composition may be determinant in potential liver damage induced by specific BA accumulation in rodents and humans, as CDCA is more toxic than CA or MCAs (9, 14) .
In conclusion, we report the development of a new analytical method for the quantitative target profiling of circulating and hepatic BAs of human, mouse and rat. The results clearly suggest that this method is a valuable tool for comparing BAs profiles between different populations (e.g., healthy, disease or treated, non treated), which is an especially important issue when searching for biomarkers and understanding liver damage mechanisms. As far as we are aware, it is one of the most comprehensive BA profiling tools described to date and, more importantly, it allows an integrated comparative analysis of both the major and minor BAs forms in human, rat and mouse samples. Key advantages of the validated method include its high sensitivity, reproducibility and its low sample requirements. An important novelty of the current study is that it provides the first comparative analysis of circulating and hepatic BA profiles of human healthy donors and by guest, on October 14, 2017 www.jlr.org
those of the two most commonly used experimental species in laboratory research with a single analytical method (9, 14) . The observed interspecies differences in serum, and particularly in hepatic BA patterns, mean that special caution is needed with conclusions from animal studies on potential biomarkers or BA profiles characteristics of a particular disease when extrapolating them to the human liver. Figures   Fig. 1 . Chromatographic separation of BAs (i.e., N5/N6) get separated and individually quantified by BA specific MRM Glycine-conjugated BAs. C: Taurine BAs were separated and detected di-hydroxylated BAs; dark blue: mono Precision is expressed as a coefficient of variation (%). Accuracy is expressed as the relative measurement error (RME) and is calculated using the following formula: RME (%) = 100 x (calculated concentration -nominal concentration)/nominal concentration. L: low concentration (40nM, each BA); M: medium concentration (312nM, each BA); H: high concentration (2500nM, each BA); ULOQ: upper limit of quantification; LLOQ: lower limit of quantification; LOD: limit of detection)
